Mateon Therapeutics (MATN) Stock Price, News & Analysis

Company Overview

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

Key Stats

• Today's Range: $0.05 to $0.06
• 50-Day Range: $0.04 to $0.07
• 52-Week Range: $0.13 to $0.38
• Volume: 42,000 shs
• Average Volume: 338,444 shs
• Market Capitalization: $5.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MATN Stock Analysis - Frequently Asked Questions

How have MATN shares performed this year?

Mateon Therapeutics' stock was trading at $0.0350 at the beginning of 2025. Since then, MATN stock has increased by 67.7% and is now trading at $0.0587.
View the best growth stocks for 2025 here.

How were Mateon Therapeutics' earnings last quarter?

Mateon Therapeutics, Inc. (OTCMKTS:MATN) posted its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02).

How do I buy shares of Mateon Therapeutics?

Shares of MATN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mateon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mateon Therapeutics investors own include Amarin (AMRN), Cyclacel Pharmaceuticals (CYCC), Catalyst Pharmaceuticals (CPRX), Oramed Pharmaceuticals (ORMP), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP) and BioLineRx (BLRX).

Company Calendar

• Last Earnings: 5/15/2019
• Today: 5/14/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MATN
• Previous Symbol: NASDAQ:MATN
• CIK: 908259
• Web: www.mateon.com
• Phone: 650-635-7000
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,640,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -64.66%
• Return on Assets: -42.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.17
• Quick Ratio: 0.17

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 0.29

Miscellaneous

• Outstanding Shares: 90,240,000
• Free Float: N/A
• Market Cap: $5.30 million
• Optionable: Not Optionable
• Beta: 1.33